Patents by Inventor Birgit Maria Reipert
Birgit Maria Reipert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210300997Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.Type: ApplicationFiled: June 14, 2021Publication date: September 30, 2021Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
-
Publication number: 20200216518Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.Type: ApplicationFiled: October 18, 2019Publication date: July 9, 2020Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
-
Patent number: 10494418Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.Type: GrantFiled: October 30, 2017Date of Patent: December 3, 2019Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
-
Publication number: 20180291087Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.Type: ApplicationFiled: October 30, 2017Publication date: October 11, 2018Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
-
Patent number: 9834593Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.Type: GrantFiled: February 18, 2015Date of Patent: December 5, 2017Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
-
Publication number: 20170267743Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.Type: ApplicationFiled: November 2, 2016Publication date: September 21, 2017Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
-
Patent number: 9512198Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.Type: GrantFiled: January 23, 2015Date of Patent: December 6, 2016Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
-
Publication number: 20150232536Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.Type: ApplicationFiled: February 18, 2015Publication date: August 20, 2015Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
-
Publication number: 20150203567Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.Type: ApplicationFiled: January 23, 2015Publication date: July 23, 2015Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
-
Patent number: 8986670Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.Type: GrantFiled: February 28, 2013Date of Patent: March 24, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
-
Patent number: 8969524Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.Type: GrantFiled: October 27, 2011Date of Patent: March 3, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
-
Patent number: 8962912Abstract: The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.Type: GrantFiled: March 24, 2011Date of Patent: February 24, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Maria Sasgary, Maria Schuster, Hans-Peter Schwarz, Birgit Maria Reipert, Gerhard Antoine, Hartmut Ehrlich
-
Publication number: 20120309021Abstract: The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.Type: ApplicationFiled: June 6, 2012Publication date: December 6, 2012Applicant: BAXTER INTERNATIONAL INC.Inventors: Christian Lubich, Juergen Siekmann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
-
Patent number: 8216793Abstract: The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.Type: GrantFiled: May 25, 2010Date of Patent: July 10, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Christian Lubich, Juergen Siekmann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
-
Publication number: 20120135019Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.Type: ApplicationFiled: October 27, 2011Publication date: May 31, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
-
Publication number: 20110070592Abstract: The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.Type: ApplicationFiled: May 25, 2010Publication date: March 24, 2011Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.AInventors: Christian Lubich, Juergen Siekmann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich